C
엘앤케이바이오
156100KOSDAQ51.0 / 100
Reference Date: 2026-10-23
Financial Score14.5 / 40
News Sentiment12.5 / 25
Momentum14.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 17.2% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Elan K Bio is a specialized medical device company focusing on the design, development, manufacturing, and sales of spinal implants used in orthopedic and neurosurgical procedures. Its products, classified as Class 3 medical devices, account for 95.9% of revenue generated primarily in the Americas.
Number of Employees
97people
Average Salary
60.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
3.86Industry Average 1.200.0Point
3.2x industry avg (risky)
ROE
-44.98Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
16.87Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲14.3% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼12.7% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -14.3% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (29%)
Current 6,670Won52-week high 15,89052-week low 2,795
1-month return6.0Point
1m +17.22% (strong rise)
Volume trend5.0Point
Volume flat
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-10-16
- Neutral[기재정정]반기보고서 (2026.06)2026-09-30